tiprankstipranks
Advertisement
Advertisement

ALMS Stock Latest News

Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
TipRanks NewswireNuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
6h ago
ALMS
NVCT
Alumis rises 10.3%
PremiumThe Fly
Alumis rises 10.3%
10d ago
ALMS
Alumis price target raised to $40 from $38 at Chardan
PremiumThe Fly
Alumis price target raised to $40 from $38 at Chardan
1M ago
ALMS
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
1M ago
ALMS
Alumis price target raised to $39 from $38 at Morgan Stanley
PremiumThe Fly
Alumis price target raised to $39 from $38 at Morgan Stanley
1M ago
ALMS
Alumis price target raised to $51 from $49 at Wells Fargo
PremiumThe FlyAlumis price target raised to $51 from $49 at Wells Fargo
1M ago
ALMS
Alumis price target raised to $34 from $32 at Guggenheim
Premium
The Fly
Alumis price target raised to $34 from $32 at Guggenheim
1M ago
ALMS
Alumis downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Alumis downgraded to Neutral from Buy at H.C. Wainwright
1M ago
ALMS
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
PremiumThe Fly
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
1M ago
ALMS
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
PremiumRatings
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
2M ago
ALMS
Alumis falls -16.1%
PremiumThe Fly
Alumis falls -16.1%
3M ago
ALMS
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
PremiumRatings
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
3M ago
ALMS
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
PremiumThe FlyAlumis shares should trade higher on ‘major success’ at AAD, says Ramond James
3M ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
Premium
The Fly
Alumis price target raised to $55 from $50 at Oppenheimer
3M ago
JNJ
TAK
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
Premium
Company Announcements
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
3M ago
8K
ALMS
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
PremiumRatings
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
3M ago
ALMS
Alumis price target lowered to $25 from $40 at H.C. Wainwright
PremiumThe Fly
Alumis price target lowered to $25 from $40 at H.C. Wainwright
3M ago
ALMS
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
PremiumThe Fly
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
3M ago
ALMS
Alumis price target raised to $38 from $33 at Morgan Stanley
PremiumThe Fly
Alumis price target raised to $38 from $33 at Morgan Stanley
3M ago
ALMS
Alumis files automatic mixed securities shelf
PremiumThe FlyAlumis files automatic mixed securities shelf
3M ago
ALMS
Alumis initiated with a Strong Buy at Raymond James
Premium
The Fly
Alumis initiated with a Strong Buy at Raymond James
3M ago
ALMS
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis
Premium
Ratings
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis
4M ago
ALMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >